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Abstract
Background: The clinicopathological features and prognosis of gastric cancer in young patients are both limited
and controversial. Therefore, the aim of this study was to define the clinicopathological features and prognosis of
gastric cancer in young patients after curative resection.
Methods: From May 2008 to December 2014, 198 young patients (age ≤ 40 years) and 1096 middle-aged patients
(55 ≤ age ≤ 64 years) were enrolled in this study. The clinicopathological features and prognosis of gastric cancer in
these patients were analyzed.
Results: Compared with middle-aged patients, the proportion of females, lower third tumors, tumor size less than 5 cm,
poorly differentiated tumors and T1 tumors were significantly higher in young patients (all P < 0.05). The proportions of
comorbidity, upper third tumors, well and moderately differentiated tumors, T4 tumors, and positive carcinoembryonic
antigen (CEA), alpha fetoprotein (AFP) and carbohydrate antigen (CA) 19–9 were significantly lower in young patients (all
P < 0.05). The distributions of N status and CA125 were comparable between young and middle-aged patients (all P > 0.
05). The five-year overall survival rates were comparable between young patients and middle-aged patients (62.8 vs 54.
7 %, P = 0.307). The tumor location, T status, N status and CA125 were independent predictors of prognosis in young
patients. The overall survival of patients with tumors located in the upper or middle third was significantly lower than for
those located in the lower third (60.8 vs 50.6 % vs 68.4 %, P = 0.016). The overall survival of CA125-positive patients was
significantly lower than CA125-negative patients (49.0 vs 64.4 %, P = 0.001).
Conclusion: The clinicopathological features were significantly different between young and middle-aged patients. The
prognosis of gastric cancer in young patients was equivalent to that of middle-aged patients. Tumor location, T status,
N status and CA125 were independent risk factors for prognosis in young patients.
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Background
Gastric cancer is the fourth most common cancer in the
world [1] and the second most common cancer in China
[2]. Although the incidence of gastric cancer in young
patients is relatively low, it has been increasing world-
wide over the past few decades [3, 4].
Data on the clinicopathological features and prognosis
of young gastric cancer patients have been both limited
and controversial. Compared with middle-aged patients,
the proportion of female patients is significantly higher
among young patients [5–9]. Furthermore, a significantly
higher frequency of histologically undifferentiated tumor
types [5, 7, 9] and N3 status [5, 7] are more common in
young patients. The prognosis in young gastric cancer
patients has been reported to comparable to that in
middle-aged patients [5, 6, 8, 9]. On the other hand,
Saito et al. [7] reported that prognosis in young gastric
cancer patients is worse than that in middle-aged
patients. Moreover, little is known about the clinicopath-
ological features and prognosis of gastric cancer in
young Chinese patients.
In light of this, we retrospectively analyzed the clinico-
pathological features and prognosis of 198 young
patients and 1096 middle-aged patients with gastric
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cancer who had been treated with curative surgical
resection. The aim of the present study was to assess the
clinicopathological features and prognosis of gastric
cancer in young patients.
Methods
Patients and data
This study was performed in the Xijing Hospital of Di-
gestive Diseases affiliated to the Fourth Military Medical
University. From May 2008 to December 2014, a total of
5285 gastric cancer patients underwent treatment in our
department. The inclusion criteria were as follows: patients
1. underwent D2 gastrectomy; 2. had no neoadjuvant
chemotherapy; and 3. had no distant metastasis. This study
was approved by the Ethical Committee of Xijing Hospital,
and written consent was obtained from all patients.
In this study, young patients were defined as those
aged 40 or under, while middle-aged patients were
defined as those within the 10-year range around the
median point in the histogram of all patients. The histo-
gram for the 5285 patients with gastric cancer is shown
in Fig. 1 and the median point for age was 58 years.
Moreover, patients aged 55–64 years in our department,
which was the largest part of the histogram, could pref-
erably represent the actual clinicopathological features
and prognosis; therefore, the 1096 patients aged 55–64
years were defined as the middle-aged patients.
Among 1294 patients, a curative proximal, distal, or
total gastrectomy with a combined standardized lymph
node dissection was performed according to the Japanese
Classification of Gastric Carcinoma standard. The patients
were followed up every 6 months after discharge until
December 2015.
Clinicopathological characteristics including age, gender,
tumor size, tumor location, histological type, T status, N
status, carcinoembryonic antigen (CEA), alpha fetoprotein
(AFP) and carbohydrate antigen (CA) 19–9 and CA125
were recorded. The tumors were staged according to the
seventh edition of the American Joint Committee on Can-
cer Tumor Node Metastasis (TNM) classification [10]. A
CEA level of 5 μg/L or less, AFP level of 8.1 μg/L or less,
CA 19–9 of 27 U/mL or less and CA125 level of 35 μg/L
or less were considered to be negative.
Statistical analysis
Chi-squared test or Fisher’s exact test was used to assess
the significant differences in the clinicopathological
characteristics. The overall survival (OS) was measured
from the time of resection until death or last follow-up.
The survival rates were calculated using the Kaplan–
Meier method; the relative prognostic importance of the
parameters was analyzed with the Cox proportional haz-
ards model. Factors generally considered to be associated
with prognosis underwent multivariate analysis. A P <
0.05 was considered to be statistically significant.
Results
The clinicopathological characteristics of 198 young pa-
tients and 1096 middle-aged patients are shown in
Table 1. Gastric cancer occurred predominantly in
women among young patients than that in middle-aged
patients (41.9 vs 18.3 %, P < 0.001). The proportion of
patients with comorbidities was significantly higher in
middle-aged patients than that in young patients (24.4
vs 4.5 %, P < 0.001). The proportion of tumors located in
the upper third was significantly higher in middle-aged
patients than that in young patients (36.1 vs 7.6 %),
while the proportion of tumors located in the lower
third was significantly higher in young patients than that
in middle-aged patients (62.1 vs 40.5 %, P < 0.001). A
tumor size larger than 5 cm was more frequent in
middle-aged patients than in young patients (50.6 vs
40.9 %, P = 0.012). The proportion of well and moder-
ately differentiated tumors in young patients was signifi-
cantly lower than that in middle-aged patients (3.5 vs
11.2 %, 8.6 vs 29.5 %); the proportion of poorly differen-
tiated tumors was significantly higher than that in
middle-aged patients (82.8 vs 53.6 %, P < 0.001). The
proportion of T1 tumors in young patients was signifi-
cantly higher than that in middle-aged patients (25.8 vs
17.5 %), while the proportion of T4 tumors in young pa-
tients was significantly lower than that in middle-aged
patients (22.2 vs 31.6 %, P = 0.012). Rates of CEA, AFP
and CA19-9 positivity in young patients were signifi-
cantly lower than that in middle-aged patients (8.1 vs
22.4 %, 1.5 vs 6.3 %, 13.1 vs 20.2 %, respectively; all P <
0.05). The distributions of N status and CA125 were
comparable between young and middle-aged patients.
The risk factors for the prognosis of gastric cancer in
young and middle-aged patients were analyzed using uni-
variate and multivariate analysis (Table 2). The results
indicated that tumor location, tumor size, histological
Fig. 1 Age histogram for all patients with gastric cancer treated at
our institution
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type, T status, N status, CEA, AFP, CA19-9 and CA125
were associated with the prognosis according to the uni-
variate analysis. Tumor size, T status, N status, CEA,
CA19-9 and CA125 were independent risk factors for
prognosis based on the multivariate analysis. Age was not
a risk factor for prognosis in either the univariate or multi-
variate analysis. The prognosis was analyzed using
Kaplan–Meier method. The median overall survival (OS)
was 27.28 (1.80–73.13) and 22.90 (1.90–75.10) months in
young and middle-aged patients, respectively. The 5-year
overall survival rates were comparable between young and
middle-aged patients (62.8 vs 54.7 %, P = 0.307, Fig. 2).
To explore the factors impacting prognosis in young
gastric cancer patients, univariate and multivariate
analyses were performed. The results showed that gen-
der, tumor size, tumor location, T status, N status,
CA19-9 and CA125 were associated with prognosis.
Moreover, tumor location, T status, N status and
CA125 were identified as independent prognostic
factors (Table 3). The overall survival of patients with
tumors located in the upper or middle third was sig-
nificantly lower than for those located in the lower
third (60.8 % vs 50.6 vs 68.4 %, respectively; P = 0.016,
Fig. 3). The overall survival of CA125-positive patients
was significantly lower than for that of negative
patients (49.0 vs 64.4 %, P = 0.001, Fig. 4).
Discussion
The clinical features and prognosis of gastric cancer in
young patients remain unclear. In addition, reports of
the clinicopathological features and prognosis of young
gastric cancer patients in China are rare. We found that
the clinicopathological features were significantly differ-
ent between young and middle-aged patients. However,
age was not an independent risk factor for the prognosis
of gastric cancer patients in either young or middle-aged
patients.
Consistent with previous studies [5–9], the proportion
of females in the young patient group was significantly
higher than that among middle-aged patients in our
study. The reason for this remains unclear. Some investi-
gators suspect that it may be partially due to the higher
Table 1 Clinicopathological features of gastric cancer in young
and middle-aged patients
Characteristics Young Middle-aged P
value(n = 198) (n = 1096)
Gender <0.001
male 115 (58.1) 895 (81.7)
female 83 (41.9) 201 (18.3)
Comorbidity <0.001
Negative 189 (95.5) 829 (75.6)
Positive 9 (4.5) 267 (24.4)
Hypertension 0 (0.0) 153 (14.0) <0.001
Coronary heart disease 0 (0.0) 22 (2.0) 0.064
Diabetes mellitus 2 (1.0) 53 (4.8) 0.014
COPDa 0 (0.0) 7 (0.6) 0.389
Brain infarction 0 (0.0) 18 (1.6) 0.094
Chronic hepatitis B 6 (3.0) 12 (1.1) 0.044
Tumor location <0.001
Upper 15 (7.6) 396 (36.1)
Middle 58 (29.3) 242 (22.1)
Lower 123 (62.1) 444 (40.5)
whole 2 (1.0) 14 (1.3)
Tumor size 0.012
< 5 cm 117 (59.1) 541 (49.4)
≥ 5 cm 81 (40.9) 555 (50.6)
Histologic type <0.001
Well differentiated 7 (3.5) 123 (11.2)
Moderately differentiated 17 (8.6) 323 (29.5)
Poorly differentiated 164 (82.8) 587 (53.6)
Signet ring cell or mucinous 10 (5.1) 63 (5.7)
T status 0.012
T1 51 (25.8) 192 (17.5)
T2 31 (15.7) 168 (15.3)
T3 72 (36.4) 390 (35.6)
T4 44 (22.2) 346( 31.6)
N status 0.067
N0 62 (31.3) 392 (35.8)
N1 27 (13.6) 205 (18.7)
N2 41 (20.7) 206 (18.8)
N3 68 (34.3) 293 (26.7)
Tumor marker
CEA <0.001
Positive 16 (8.1) 245(22.4)
Negative 182 (91.9) 851 (77.6)
AFP 0.007
Positive 3 (1.5) 69 (6.3)
Table 1 Clinicopathological features of gastric cancer in young
and middle-aged patients (Continued)
Negative 195 (98.5) 1027 (93.7)
CA19-9 0.020
Positive 26 (13.1) 221 (20.2)
Negative 172 (86.9) 875 (79.8)
CA125 0.152
Positive 14 (7.1) 51 (4.7)
Negative 184 (92.9) 1045 (95.3)
a COPD: chronic obstructive pulmonary disease
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expression of estrogen receptors in young female patients
with gastric cancer [11–13]. Moreover, Kath et al. [14]
suggested that the preponderance of female among young
patients may be attributed to an association with recent
pregnancies. Therefore, estrogen may play a role in the
pathogenesis of gastric cancer in young patients; however,
this hypothesis requires further investigation [15].
In previous studies [5–7, 9], the proportion of undiffer-
entiated tumors is significantly higher in young patients
than that in middle-aged patients. In the current study,
there was no significant difference in the proportion of
signet ring cell carcinoma and mucinous adenocarcinoma
between the two groups. However, the proportion of
poorly differentiated tumors was significantly higher in
young patients than in middle-aged patients. Some
authors attributed these results to the H. pylori infection.
Haruma et al. [16] reported that 95 % of the poorly differ-
entiated cases are positive for H. pylori infection in
patients younger than 30. In addition, Hirahashi et al. [17]
found that the proportion of H. pylori infection is signifi-
cantly higher in young patients than in middle-aged
patients and suggested that H. pylori infection may con-
tribute to the development of poorly differentiated gastric
cancer in the young.
Only one report found a significant difference in tumor
location between young and middle-aged patients; tumors
located in the upper third is more common in middle-aged
patients [7]. Our results were consistent with this finding.
We know that cardiac cancer arises via cardiac intestinal
metaplasia, which is primarily due to gastroesophageal
reflux disease [18–20]. In addition, the incidence of gastro-
esophageal reflux disease increases with age [21, 22], which
may result in a higher proportion of upper third tumors in
the middle-aged patients.
Previous studies showed that positive rates of CEA,
AFP, CA19-9 and CA125 tends to be higher in elderly
patients [23–28]. Moreover, we found that higher posi-
tive rates of serum CEA, AFP and CA19-9 were also
correlated with older age in non-elderly gastric cancer
patients. It has been widely reported that higher rates of
serum CEA, AFP and CA19-9-positivity in gastric cancer
are correlated with larger tumors, higher T status, and
upper third tumor [24, 29, 30]. Therefore, higher posi-
tive rates of serum CEA, AFP and CA19-9 in the
middle-aged patients of our present study may be a
result of the higher proportion of larger tumor size, T4
status and upper third tumors in middle-aged group. In
contrast to the previous report, the rate of positive
CA125 was higher in young patients than in middle-
aged patients, although the difference was not signifi-
cant. It has been reported that higher rates of CA125
positivity are associated with middle and lower third
tumors [26, 31]. Therefore, the higher proportion of
Table 2 Survival analysis of the 1294 gastric cancer patients
Parameter Univariate Analysis Mutivariate Analysis
β HR (95 % CI) P value β HR (95 % CI) P value
Age (young/older group) 0.152 0.859 (0.642–1.150) 0.307 −0.001 0.999 (0.727–1.372) 0.993
Gender (male/ female) 0.234 1.264 (0.996–1.605) 0.054 0.163 1.177 (0.916–1.513) 0.202
Comorbidity (negative/ positive) 0.078 1.082 (0.824–1.420) 0.572 −0.027 0.973 (0.735–1.288) 0.848
Tumor location (upper/middle/lower third /whole) −0.139 0.870 (0.774–0.977) 0.019 −0.042 0.958 (0.848–1.083) 0.496
Tumor size (<5 cm/≥5 cm) 1.066 2.905 (2.320–3.637) 0.000 0.238 1.268 (1.014–1.587) 0.038
Depth of invasion (T1/T2/T3/T4) 0.824 2.280 (2.000–2.599) 0.000 0.492 1.636 (1.408–1.901) 0.000
Lymph node metastasis (N0/N1/N2/N3) 0.730 2.075 (1.880–2.290) 0.000 0.505 1.657 (1.482–1.852) 0.000
Histologic type (well/moderately/poorly / signet ring cell or mucinous) −0.194 0.824 (0.726–0.935) 0.003 −0.050 0.951 (0.840–1.078) 0.436
CEA (negative/ positive) 0.841 2.318 (1.848–2.907) 0.000 0.352 1.422 (1.110–1.822) 0.005
AFP (negative/ positive) 0.640 1.896 (1.325–2.712) 0.000 0.325 1.384 (0.952–2.011) 0.088
CA19-9 (negative/ positive) 0.834 2.303 (1.839–2.882) 0.000 0.365 1.441 (1.137–1.825) 0.002
CA125 (negative/ positive) 1.176 3.242 (2.274–4.622) 0.000 0.729 2.073 (1.442–2.979) 0.000
Fig. 2 Comparison of overall survival between in young and
middle-aged patients
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middle and lower third tumors in young patients in the
present study may explain the current results.
In the present study, age was not an independent risk
factor for the prognosis of gastric cancer by univariate
and multivariate analyses. Most of the previous studies
also reported that the prognosis of gastric cancer is
comparable between young and middle-aged patients
[5, 6, 8, 9]. Only one report showed that the prognosis
of the middle-aged patients is significantly better than
that of young patients and suggested that age should be
a predictor of survival in patients with gastric cancer
[7]. This may have been attributed to the relatively
small sample size of the latter study.
According to the univariate and multivariable ana-
lyses, the independent risk factors for the prognosis
of young patients were tumor location, T status, N
status and serum CA125. However, the tumor size
and histologic type, which are widely known as risk
factors for tumor-related death [6, 32, 33], did not
demonstrate a correlation with survival in young pa-
tients in the present study. This may result from
differences in race, sample size, etc. In the present
study, better survival was observed in patients with
lower third tumors than in those with upper and
middle third tumors. Liu et al. [34] also found that
the 3-year survival rate is significantly higher in the
distal gastric adenocarcinoma group than that in the
esophagogastric junctional adenocarcinoma group
after R0 resection. It was reported that AFP, CEA and
CA19-9 are independent prognostic factors for gastric
cancer [27–29, 35]. However, AFP, CEA and CA19-9
did not show prognostic value for young gastric can-
cer patients in the present study. This may a result of
the relatively small number of young gastric patients
in the present study.
There are limitations to our study. First, a single
hospital-based design might have led to an uncertain
amount of selection bias. Second, this was a retrospect-
ive analysis; a well-designed randomized clinical trial
should be carried to avoid statistical bias in the future.
Third, not all of the patients enrolled in our study
reached the 5-year follow-up.
Table 3 Survival analysis of the 198 young gastric cancer patients
Parameter Univariate Analysis Mutivariate Analysis
β HR (95 % CI) P value β HR (95 % CI) P value
Gender (male/ female) 0.557 1.746 (1.017–2.997) 0.043 0.015 1.015 (0.572–1.800) 0.959
Comorbidity (negative/ positive) −3.082 0.046 (0.000–10.360) 0.265 −11.166 0.000 (0.000-NA) 0.973
Tumor location (upper/middle/lower third /whole) −0.487 0.615 (0.427–0.886) 0.009 −0.407 0.665 (0.428–1.035) 0.048
Tumor size (<5 cm/≥5 cm) 1.063 2.894 (1.651–5.076) 0.000 0.342 1.407(0.737–2.688) 0.301
Depth of invasion (T1/T2/T3/T4) 1.001 2.722 (1.915–3.868) 0.000 0.461 1.586 (1.067–2.358) 0.023
Lymph node metastasis (N0/N1/N2/N3) 1.226 3.406 (2.349–4.939) 0.000 1.066 2.905 (1.932–4.366) 0.000
Histologic type (well/moderately/poorly / signet ring cell or mucinous) −0.216 0.806 (0.534–1.217) 0.304 −0.052 0.949 (0.638–1.413) 0.797
CEA (negative/ positive) 0.640 1.896 (0.856–4.200) 0.115 0.428 1.534 (0.608–3.871) 0.365
AFP (negative/ positive) −3.026 0.049 (0.000–913.653) 0.547 −11.184 0.000 (0.000-NA) 0.986
CA19-9 (negative/ positive) 1.036 2.817 (1.505–5.272) 0.001 0.382 1.466 (0.710–3.026) 0.301
CA125 (negative/ positive) 1.260 3.527 (1.578–7.886) 0.002 1.087 2.965 (1.221–7.203) 0.016
Fig. 3 Overall survival in young patients based on tumor location Fig. 4 Overall survival in young patients based on level of CA125
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Conclusion
The clinicopathological features were significantly differ-
ent between young and middle-aged gastric cancer pa-
tients, but the prognosis of gastric cancer in young
patients was equivalent to that in middle-aged patients.
Tumor location, T status, N status and CA125 levels
were independent risk factors for the prognosis in young
patients.
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